The Society for Healthcare Epidemiology of America (SHEA) says it is dedicated to the prevention of infection in healthcare settings, including the protection of healthcare personnel (HCP) who provide care to patients with known or suspected Ebola virus disease (EVD). SHEA says it supports the current Centers for Disease Control and Prevention (CDC) guidance on personal protective equipment (PPE) to be used by HCP caring for patients with EVD. This guidance is consistent with the established science regarding how EVD is transmitted.
Recently updated guidance from California’s Division of Occupational Safety and Health (Cal/OSHA) meets the CDC recommendations, but specifies only one form of respiratory protection (powered air purifying respirator (PAPR)) and only one form of barrier protection (impermeable coverall) for all inpatient and emergency department (ED) care of those with suspected or confirmed EVD. However, there are no data to suggest that these specific forms of PPE provide better protection for HCP than alternatives that are also included in CDC guidance (e.g., N95 respirators, fluid impermeable hoods, AAMI-4 gowns and leg coverings).
There are several types of PPE that provide full protection against Ebola transmission, and the local preference of nurses, physicians and other HCP is paramount to select the best PPE for their facility (from among CDC-adherent options). Considerations of familiarity, tolerability (e.g. discomfort, overheating), risk for self-contamination during doffing, and amenability to training all require local input. Thus wide adoption of the narrow requirements established by Cal-OSHA could have unintended adverse consequences. For example, hospitals that have already trained their HCP in safe use of AAMI-4 gowns may inadvertently increase exposure risk by switching to unfamiliar coveralls that are widely considered to be more difficult to doff without self-contamination. Furthermore, mandating PPE that is excessive for the fluid risk of a suspected or confirmed EVD patient results in unnecessary impediments to timely and effective clinical care (e.g., requiring PAPR and coverall for evaluation of an ED patient with low grade fever and no other symptoms). Since most suspected EVD patients cared for in U.S. hospitals test negative for EVD but may have other life threatening conditions that require timely therapy (e.g., malaria), such impediments can lead to harm. Finally, unnecessarily narrow limitations on PPE types will exacerbate already critical PPE shortages and limit the ability of US hospitals to be prepared to care for those with known or suspected EVD.
SHEA says that HCP have a right to a safe work environment during the care of patients with any communicable disease, including Ebola. SHEA believes that the current CDC guidance, when practiced correctly and reinforced by adequate training of HCP, protects HCP from Ebola transmission.
Source: SHEA
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.